Arrowhead Research | ARWR - Ebit



金融业
股票价格
USD
资产
USD 2.11B
现金及等价物
USD 19.69M
流动资产
USD 1.67B
流动负债
USD 283.35M
债务
USD 983.69M
EBIT
USD -154.34M
EBITDA
USD -147.68M
员工
711
EPS每股收益
USD -1.36
股本和储备
USD 465.53M
销售毛利
USD 75.25M
债务利息支出
USD 24.56M
利息收入
USD 16.94M
贷款资金
USD 824.07M
市值
USD 10.83B
净收入
USD -194.28M
营业费用
USD 245.35M
营业利润
USD -170.09M
普通股股本
USD 141.14M
PE价格收益
39.19
税前利润
USD -178.91M
销售收入
USD 75.23M
销售和管理费用
USD 46.63M
股票
USD -173.09M
贸易债权人
USD 27.78M
应收帐款人
USD 8.56M


Ebit 更改 日
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD -154.34M 13.08M 2026-06
Heron Therapeutics USD 38K 3.83M 2025-12
Incyte USD 700.4M 356.23M 2026-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
Ligand Pharmaceuticals USD 56.62M 3.7M 2026-06
Merck USD 840M 2.72B 2026-06
Moderna USD -815M 573M 2026-06
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Novartis USD 4.73B 549M 2026-06
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
TG Therapeutics USD 21.67M 13.12M 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
Vertex Pharmaceuticals USD 1.27B 129.9M 2026-06
Xencor USD -36.6M 41.26M 2026-06